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Abstract Recent findings from genetic studies suggest that
defective mitochondrial quality control may play an impor-
tant role in the development of Parkinson's disease (PD).
Such defects may result in the impairment of neuronal
mitochondria, which leads to both synaptic dysfunction and
cell death and results in neurodegeneration. Here, we review
state-of-the-art knowledge of how pathways affecting mito-
chondrial quality control might contribute to PD, with a
particular emphasis on the molecular mechanisms employed
by PTEN-induced putative kinase 1 (PINK1), HtrA2 and
Parkin to regulate mitochondrial quality control.
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Introduction
Parkinson's disease (PD) is a neurodegenerative disorder of
the central nervous system that belongs to a group of
conditions referred to as movement disorders. Efforts to
understand the genetic basis of this disease have led to the
identification of a number of gene mutations accounting for
a small proportion of PD cases. Although the role of
mitochondria in PD has been debated inconclusively in the
past few decades, it was the identification of PD-causative
mutations in the mitochondrial putative protein kinase
PINK1 that helped reignite the interest in the potential role
of this organelle in the pathophysiology of familial PD. It is
now becoming clear that PINKI acts in a mitochondrial
quality control pathway and that other genes implicated in
this disease are under its control. This suggests that a subset
of genes involved in PD converge in a common pathway
that modulates the fidelity of mitochondria. Given that most
PD cases are sporadic with no known specific cause, this
raises the interesting hypothesis that impaired mitochondri-
al quality control might be a defining causative feature of
this disease. The purpose of this review is to summarise
some of the recent molecular determinants of mitochondrial
quality control regulated by PINK1.
Mitochondria: A Force for Life and Death
Midichlorians are microorganisms in the fictional Star Wars
galaxy. These microscopic life forms reside within cells of
all living things and communicate using the Force. The
Force is an energy field created by all living things and
harvested by the Jedi knights to protect the galaxy. The
Force, however, has a ‘Dark Side’, and it can therefore be
employed to cause death and destruction. Midichlorians not
only help to communicate the Force, but they are also
symbionts with all living things. Without them, life could
not exist. The creator of Star Wars, George Lucas, stated
that the midichlorians are based on the endosymbiotic
theory, which explores the origin of mitochondria and
plastids present in eukaryotic cells. In fact, midichlorians
are loosely based on mitochondria, an organelle that
sustains life in eukaryotic cells of multicellular organisms;
however, these organelles are also known to bring about
death and destruction within cells.
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DOI 10.1007/s12035-010-8150-4It is widely accepted that the acquisition of mitochondria
is a crucial event in the evolution of the eukaryotic cell [1].
According to the endosymbiotic theory, mitochondria
evolved from a metabolically driven symbiotic relationship
between aerobic bacteria and a nucleus-containing cell. As
descendants of the original symbiont, mitochondria are
organelles highly efficient in their ability to utilise
molecular oxygen (O2) and organic substrates, such as
glucose and pyruvate, and to produce cellular energy in the
form of ATP. The molecular machinery present in mito-
chondria for energy production is collectively referred to as
the electron transport chain (ETC). The ETC consists of
four protein complexes. Three of the complexes (I, III and
IV) pump protons (H
+) outwardly across the inner
membrane to establish a gradient necessary for the
production of ATP by a molecular motor (complex V or
ATP synthase). During electron transport, O2 is converted
to H2O, and, particularly at complexes I and II, the free
radical superoxide O2
  ðÞ is also generated as a by-product.
Two important cofactors that modulate energy and free
radical production are coenzyme Q10 at complex II and
cytochrome c at complex IV [2]. It is noteworthy that
excessive production of superoxide can enhance oxidative
stress in dopaminergic neurons, eventually contributing to
the demise of these cells in PD [3].
Mitochondria play a key role in eukaryotic cells by
supplying the majority of the cellular energy in the form of
ATP. However, a cell death-related role for this organelle is
also now clearly established. When eukaryotic cells in
multicellular organisms become worn out or damaged, they
undergo cellular suicide (i.e. apoptosis). During this
process, the cell blebs, shrinks and is packaged for
recycling. When this process lacks proper control, either
decreased or increased cell loss can occur, leading to
diseases such as cancer or neurodegeneration. Apoptosis is
actively controlled by mitochondria. When the mitochon-
drial pathway of apoptosis is activated, these organelles
release several proteins that activate several proteases and
other hydrolytic enzymes, leading to proteolysis, DNA
fragmentation and chromatin condensation. The main
mitochondrial effectors of apoptosis are proteins that
paradoxically play important survival roles in non-
apoptotic cells. These effectors include cytochrome c,
which, in normal settings, is a component of the ETC,
and the serine protease HtrA2 (also known as Omi) which
seems to play a protective role during stress in the
mitochondria of healthy cells [4]. The mitochondrial
pathway of apoptosis is regulated by the BCL-2 family
proteins (reviewed in Youle and Strasser [5]) and involves
the activation of BCL-2 family members, such as BAX and
BAK, which act by forming pores in the outer mitochon-
drial membrane (OMM) and allow the release of several
pro-apoptotic proteins from the intermembrane space into
the cytosol. The role of enhanced apoptosis as a causative
mechanism for the death of dopaminergic neurons in PD
patients is still controversial [6]. However, given that
healthy mitochondria contain a multitude of molecules that,
when released into the cytosol, lead to apoptotic cell death,
it is reasonable to assume that the compromise of
mitochondrial function in dopaminergic neurons contributes
to their demise through the engagement of this form of cell
suicide.
Totally Addicted to Mitochondria
In humans, most of the energy supplying the brain is
generated by mitochondria. The majority of this energy is
used for reversing the movement of ions that bring about
action potentials and synaptic transmission in neurons.
Neurons have very low glycolytic rates (reviewed in
Bolanos and Almeida [7]) and therefore require mitochon-
dria for energy production. Mitochondria also sequester and
buffer cytoplasmic calcium; thus, their localisation plays a
role in local regulation of intracellular calcium dynamics.
Neurons are large, specialised cells, and the biogenesis of
mitochondria in neurons takes place in the soma. This
means that mitochondria normally have to travel large
distances to deliver energy. Impressively, these organelles
will travel up to 1 m in human motor neurons and, taking
into account their maximum travelling speed, will take a
minimum of 8 days to reach their destination. The majority
of long-distance mitochondrial transport is mediated by
motor proteins powered by ATP hydrolysis that shuttle
mitochondria along microtubules (reviewed in MacAskill
and Kittler [8]). Such mitochondrial transport is bidirec-
tional, as damaged mitochondria may need to travel back to
the cell soma for autophagic degradation. This degradation
is mediated through autophagy, a molecular recycling
programme for impaired and defective cellular components.
In neurons, the synaptic terminals are sites of high
energy demand. Therefore, these structures rely heavily on
mitochondria for energy production. Synaptic transmission
requires high levels of cellular ATP for numerous energy-
consuming processes, including the maintenance of synap-
tic membrane potential and reloading of synaptic vesicles
with neurotransmitters. In addition, synaptic terminals may
require mitochondria for efficient sequestration of calcium
ions (Ca
2+) that are released into the cytosol to elicit the
fusion of synaptic vesicles with the plasma membrane
(reviewed in Ly and Verstreken [9]). Adult dopaminergic
neurons of the substantia nigra pars compacta (SNc) that
degenerate in PD are known to generate action potentials in
the absence of any synaptic input. The mechanism behind
this autonomous firing capacity involves ion channels that
enable the entry of Ca
2+ into the cytosol (reviewed by
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2+ is actively
removed by active pumping across the plasma membrane or
sequestration in the lumen of the endoplasmic reticulum
(ER) or the mitochondrial matrix, a process that requires
energy in the form of ATP. Also, active Ca
2+ buffering by
mitochondria is likely to have a significant effect in the
physiology of this organelle. It is therefore attractive to
propose that the premature death of dopaminergic neurons
in the SNc might be precipitated by a failure to control
calcium homeostasis linked to a compromise of mitochon-
drial function.
As mentioned above, neurons are specialised cells that
have foregone the capacity to undergo cell division in the
adult brain. Mitochondria are essential for energy genera-
tion in neurons. As previously stated, however, mitochon-
dria can also bring about cellular demise through apoptosis.
It is therefore essential to keep the destructive power of this
organelle under strict control. The release of apoptotic
machinery from mitochondria in neuronal cells can have
serious consequences. It is thought to play a role in the
progression of neurodegenerative disease in humans. Thus,
it is conceivable that mitochondrial dysfunction may, at an
early stage, trigger deficits in neurons prior to synapse
formation, resulting in loss of connectivity, whereas
overwhelming damage might induce apoptosis and cause
neuronal death (Fig. 1).
Parkinson's Disease: Poisons to Genes
Parkinson’s disease (PD) is a common neurodegenerative
disease characterised initially by the loss of dopaminergic
neurons in the substantia nigra and later by a more
widespread loss of other neurons in the brain. Most PD
cases occur sporadically (i.e. they are of unknown cause).
Between 10% and 15% of PD patients, however, have a
family history of the disease, indicating that there is a
strong genetic basis for this disease in this subgroup. The
molecular pathogenesis of sporadic PD and the basis for
selective dopaminergic neuronal loss remains unknown,
and it is unclear whether gene mutations are involved in the
development of this disease in this subgroup of patients.
Epidemiological studies consistently link exposure to
pesticides to a higher incidence of PD. In particular,
pesticides such as rotenone and paraquat have been shown
to cause PD-like conditions in rodent models. In addition,
the mitochondrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) was shown to be responsible for the
onset of severe PD-like symptoms in a group of young drug
users in the 1980s. It is clear that such drugs affect the ETC
in mitochondria, resulting in loss of ATP and perhaps an
increase in free-radical generation. This evidence suggests
that exposure to mitochondria-damaging agents might be
important in the aetiology of PD in the sporadic patient
population. Even though mitochondrial dysfunction has
been inconclusively linked to PD in the past few decades,
genetic evidence indicating mitochondrial involvement in
this disease was obtained only recently. A major break-
through occurred in a recent study in which researchers
identified disease-causing mutations in PTEN-induced puta-
tive kinase 1 (PINK1) in familial PD [11]. More recently,
mutations in the mitochondrial serine protease HtrA2 were
reported to be associated with PD [12]. The role of HtrA2 in
familial PD, however, remains controversial.
PINK1: Lessons from Imperfect Models
PINK1 is a putative mitochondrial kinase that acts to
protect neurons from oxidative stress. In addition, it
controls mitochondrial morphology in mammals and insects
(reviewed in Thomas et al. [13]). Although animal models
of PD fail to recapitulate all of the features of PD pathology
in humans [14], they have proven to be invaluable tools for
elucidating some of the mechanisms through which PINK1
affects mitochondrial function. Although the currently
accepted models suggest that PINK1 is a kinase, its direct
substrates have so far remained elusive. Perhaps the best
evidence to indicate that the kinase activity of PINK1 is
required for its protective function comes from studies from
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Fig. 1 Consequences of mitochondrial dysfunction in neurons.
Neurons are large, specialised cells that rely on mitochondria for the
majority of their energetic needs. A healthy mitochondrial population
ensures the delivery of ATP as a source of energy and acts as a
calcium buffering system, decreasing the concentration of this ion in
the cytosol. At synapses, defective mitochondria are likely to be less
capable of producing ATP and buffering calcium, possibly affecting
efficient synaptic transmission. If these mitochondrial defects go
unchecked, mitochondria will ultimately release pro-apoptotic factors,
and, if this process occurs in the vicinity of the cell body, it is likely to
result in neuronal death through apoptosis
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that a kinase-inactive version of Pink1 failed to rescue the
phenotypical features of pink1 loss-of-function flies [15].
The fruit fly has proven to be an important tool in the
dissection of the molecular determinants of pink1 function.
These studies, however, have presented conflicting data
regarding the importance of this gene for the survival of
dopaminergic neurons (see [16, 17]).
Recently, it was reported that a loss of PINK1 in mice
leads to a significant decrease in dopamine release and a
subsequent impairment of striatal synaptic plasticity, even
in the absence of dopaminergic neuronal degeneration [18].
In Drosophila neurons, Pink1 deficiency also seems to
affect synaptic function. Loss of Pink1 affects mitochon-
drial function and leads to a decrease in the ATP levels that
prevents synaptic vesicles from being mobilised during
rapid stimulation [19]. In addition, loss of PINK1 in mice
may also affect synaptic activity due to defects in
mitochondrial calcium handling. Abramov and colleagues
proposed that PINK1 regulates calcium efflux from
mitochondria via the mitochondrial Na
+/Ca
2+ exchanger.
Deregulation of mitochondrial calcium handling can result
in mitochondrial calcium overload that affects synaptic
function. Such an overload leads to increased levels of
reactive oxygen species (ROS), which can then lead to
mitochondria-dependent apoptosis [20]. Altogether, despite
the limitations of PD models in non-primate animal species,
both mice and flies have provided us with valuable clues
regarding the mechanisms through which PINK1 regulates
mitochondrial function.
Neuronal Mitochondria, the Good, the Bad
and the Ugly
Neurons require mitochondria to function, and in the past few
years, numerous findings have suggested that disruptions of
mitochondrialfunctionanddynamicscontributetoageingand
neurodegenerative diseases (recently reviewed in de Castro et
al. [21]). The emerging view is that eukaryotic cells have
developed exquisite mechanisms to cope with the diverse
challenges imposed on mitochondrial integrity (Fig. 2).
Mitochondria are therefore thought to have at least two
levels of defence mechanisms that ensure their integrity and
viability in individual cells (reviewed in Tatsuta and Langer
[22]). The first line of defence is comprised of highly
specific molecular quality control machinery composed of
molecular chaperones and energy-dependent proteases that
monitor the folding and assembly of mitochondrial proteins.
In addition, these molecules prevent the accumulation of
damaged proteins from mitochondria. This mitochondrial
stress signalling results in the selective transcriptional up-
regulation of nuclear genes encoding for mitochondrial
Hsp70 and Hsp60 in cells experiencing elevated mitochon-
drial protein-conformational stress, therefore suggesting the
existence of an unfolded protein response of mitochondrial
origin (UPR
mt). One of the major upstream components of
this signalling pathway in the worm Caenorhabditis elegans
has been recently found to be the orthologue of Escherichia
coli ClpP, a molecule that functions in the bacterial heat-
shock response (reviewed in Broadley and Hartl [23]). These
interesting observations suggest that mitochondria, as
descendants of the original endosymbiont, have co-opted
certain molecules of bacterial origin to stress signalling
functions.
Once molecular quality control is overwhelmed within
mitochondria, a second line of defence, termed organellar
quality control, is thought to take over. This mechanism
relies on the dynamic nature of mitochondrial populations
to ensure the disposal of defective components. Mitochon-
drial dynamics are thought to be important in the control of
mitochondrial turnover and bioenergetic efficiency. The
combined functions of fusion, fission and autophagy are
now emerging as essential organellar quality control
mechanisms that promote the sequestration, sorting and
elimination of functionally impaired mitochondria [24].
Finally, if both of these lines of defence fail, severe
mitochondrial damage unleashes the apoptosis pathway
that culminates with cell death.
Is it possible that the demise of dopaminergic neurons in
PD results from a failure of either one of the two described
quality control mechanisms in mitochondria? A positive
answer to this question is starting to emerge from recent
data derived from genetic studies in model organisms.
xThe first link between PD and mitochondrial molecular
quality control was suggested by the finding of heterozy-
gous missense mutations in HtrA2 in sporadic cases of PD
[12]. The serine protease HtrA2 was initially identified as a
mammalian homologue of the E. coli proteases HtrA/DegP
and DegS [25]. The structural and biochemical similarity of
mammalian HtrA2 to the bacterial DegS protease is
particularly striking [26–28]. In Gram-negative bacteria,
the DegS protease is involved in a signal transduction
pathway that senses and responds to envelope stress
(reviewed in Ruiz and Silhavy [29]). In mammalian cells,
HtrA2 normally resides in the mitochondrial intermembrane
space. Given the similarities between DegS and HtrA2 and
taking into account that bacteria are the most likely
ancestors of mitochondria, it is possible that HtrA2 evolved
from DegS and now controls the levels of unfolded proteins
in mitochondria.
The characterisation of mice lacking HtrA2 showed that
loss of this protease results in a neurodegenerative
phenotype with parkinsonian features. This phenomenon,
however, is not due to the loss of dopaminergic neurons; it
is instead caused by the loss of a subpopulation of striatal
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show increased levels of unfolded components of the ETC
[30], indicating that this protease is an important compo-
nent of the molecular quality control in mitochondria and
that disturbances in related quality control mechanisms
might underlay parkinsonian neurodegeneration.
In bacteria, the DegS protease is activated by unfolded
outer-membrane porins. Studies focusing on the mecha-
nisms of activation of mammalian HtrA2 have shown that
this protease is likely to be activated through PINK1-
dependent phosphorylation. These observations, however,
have failed to demonstrate direct phosphorylation of HtrA2
by PINK1 and suggest that PINK1 might instead act as a
mitochondrial adaptor for the p38 stress-activated kinase
[31]. Plun-Favreau et al. showed that PINK1 is involved in
the phosphorylation of HtrA2; however, this protease is
unlikely to be a direct target of the putative kinase activity
of PINK1. Taken together, these findings suggest that
HtrA2 is possibly a downstream effector of PINK1 in a
mitochondrial molecular quality control pathway.
The emerging picture suggests that PINK1 is a modula-
tor of not only molecular but also organellar quality control
in mitochondria. Surprisingly, it was shown that PINK1 is
capable of recruiting Parkin, a cytosolic ubiquitin ligase, to
damaged mitochondria [32, 33] and targeting these organ-
elles for autophagic clearance. The importance of Parkin as
a downstream effector of PINK1 has been further con-
firmed from a series of impressive genetic studies in
Drosophila that showed that expression of parkin could
rescue the phenotype of pink1 mutant flies [16, 17, 34].
Ubiquitin has been suggested to act as a signal for the
selective autophagy of diverse cargos, including protein
aggregates, ribosomes, peroxisomes and pathogens in
mammalian cells [35]. It seems that, in damaged mitochon-
dria, PINK1 recruits Parkin to catalyse the ubiquitination of
proteins close to the outer mitochondrial membrane. Two of
the recently identified mitochondrial substrates for Parkin
are the voltage-dependent anion channel 1 (VDAC1) [36]
and Mitofusin (Mfn) [37]. It remains to be determined if
these are specific substrates for Parkin or, upon PINK1-
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Fig. 2 Dynamics of mitochondrial quality control. Mitochondria are
dynamic organelles that are continuously remodelled by fusion and
fission events. In this figure, mitochondrial fission is represented as
one step of the mitochondrial life cycle involved in the maintenance of
a pool of viable mitochondria. In this model, mitochondria can also
employ fission to segregate defective daughter mitochondria based on
a mechanism that requires OPA1. These defective mitochondria can
follow three separate routes. They can be repaired through molecular
quality control pathways that possibly involve p38, PINK1 and HtrA2.
The defective mitochondria can also be selectively removed through
autophagy using a mechanism that involves the PINK1-dependent
recruitment of the ubiquitin ligase Parkin (1), followed by the
ubiquitination of proteins such as VDAC1 and MFN2 (orange and
green colours, respectively; purple ubiquitin) (2). Such ubiquitinated
proteins might then work as adaptors for p62/SQSTM1 and promote
the translocation of defective mitochondria to the autophagosome.
Finally, if both molecular and organellar quality control mechanisms
fail, mitochondria will ultimately release pro-apoptotic proteins (as
indicated on the upper right of the figure), leading to cell death
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“labels” any outer membrane protein with ubiquitin. The
mechanism through which ubiquitin targets defective
mitochondria for autophagy remains unclear. The mamma-
lian adaptor protein p62/SQSTM1 (sequestosome-1) is an
autophagy receptor that can interact with ubiquitin conju-
gated to a target protein as well as LC3/GABARAP on
autophagosomes [35]. It is therefore possible that ubiqui-
tinated proteins on the outer mitochondrial membrane use
p62/SQSTM1 as an adaptor to anchor defective mitochon-
dria to the autophagosome. This model is supported by a
recent study in which p62/SQSTM1 was found to be
recruited to clustered mitochondria and to be essential for
their final clearance [36].
Taken together, the findings to date suggest that PINK1
is a master regulator of mitochondrial quality control, at
least at two levels; it enhances molecular quality control via
HtrA2 and enhances organellar quality control via Parkin. It
is worth noting that mutations of all of these molecular
components of mitochondrial quality control have been
linked to PD, suggesting that alternative hits on this
common pathway are possibly important in the develop-
ment and progression of this disease.
Concluding Remarks
It is clear that unfolded proteins play an important role in
the development of PD. Although clear mechanisms for
such proteinopathies are well established when these
unfolded proteins accumulate in the cytosol, cell nucleus,
endoplasmic reticulum and extracellular space, little is
known about any causative role of protein aggregation in
mitochondria in PD. Although they have limitations, animal
models are beginning to unravel a significant role for this
phenomenon in PD when PINK1-mediated mitochondrial
quality control is impaired.
The molecular pathogenesis of sporadic PD and the basis
for selective dopaminergic neuronal loss remains unknown,
and it is unclear if there is a genetic basis for the
development of this disease in this subgroup of patients.
Recently, several genome-wide association studies (GWAS)
have been conducted to evaluate the possible genetic basis
for PD in sporadic patients. To date, such approaches have
failed to identify any genes associated with mitochondrial
dysfunction in evaluated patients. Given that multiple low-
frequency risk variants are below the detection limit of
current GWAS methodology (see [38]), it is unclear
whether mitochondrial gene mutations play any important
role in the aetiology of PD in sporadic patients. With the
increasing power of gene sequencing technologies, however,
it is likely that, if other mitochondrial mutations in PD
patients exist, they will come to light in the near future.
Approximately 40 years ago, US President Richard
Nixon declared war on cancer by increasing research
funding to improve the understanding of cancer biology.
At first glance, cancer and neurodegeneration seem to have
little in common. Neurodegeneration can be viewed as
resulting from the death of postmitotic neurons, whereas
cancer cells show an enhanced resistance to cell death. It is
now clear that mitochondria are the master controllers of
cell survival and death. Interestingly, mitochondrial PINK1
has been recently shown to be important as a survival
mechanism downstream of the PI3K/Akt signalling path-
way [39]. This pathway is often overactive in cancer cells,
suggesting that PINK1 could have oncogenic potential
through the protection of healthy mitochondria in cancer
cells. Therefore, we reason that understanding the function
of PINK1 might help to fight the war on two fronts, as this
knowledge will contribute to the elucidation of the role of
mitochondria in both cancer and neurodegeneration.
By increasing our knowledge of the power of mitochon-
dria to control cellular life and death, modern scientists can
be compared to the Jedi knights of the fictional Star Wars
galaxy, who harnessed the power of midichlorians to fight
the ‘Dark Side’. We hope that, eventually, the ‘Dark Side’
will not prevail and that such knowledge will one day
translate into cures for devastating diseases such as PD.
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